PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics Limited has announced a significant breakthrough in treating Phelan-McDermid Syndrome (PMS), a rare neurodevelopmental disorder with no existing treatments. The company’s innovative RNA therapy has successfully restored deficient SHANK3 protein levels in brain cells derived from a PMS patient, paving the way for human trials anticipated to begin in 2025. This advancement offers hope for addressing the underlying cause of PMS, potentially improving the lives of those affected by the genetic condition.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
